Gottlieb Outlines Opioid Fight
FDA’s new commissioner asks staff for suggestions for fighting the opioid crisis.
On May 23, 2017, FDA Commissioner Scott Gottlieb, MD, posted a blog post detailing his plans to fight the opioid addiction crisis, including a new steering committee. The commissioner also asked his staff for their input on how to combat this important health issue.
One of the first parts of the agency’s plan is the creation of the Opioid Policy Steering Committee, which will consist of FDA senior leaders. The committee is charged with reviewing the need for education for healthcare professions, the possible tailoring of the number of dosages, and the agency’s framework for assessing opioid abuse.
“Working together, we need to do all we can to get ahead of this crisis. That’s why we’ll also be soliciting public input, through various forums, on what additional steps FDA should consider. I look forward to working closely with my FDA colleagues as we quickly move forward, capitalizing on good work that has already been done, and expanding those efforts in novel directions. I will keep you updated on our work as we continue to confront this epidemic,” Gottlieb stated in the blog post.
Source: FDA
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
